7D2A Stock Overview
A medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sedana Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.90 |
| 52 Week High | SEK 2.39 |
| 52 Week Low | SEK 0.90 |
| Beta | 0.42 |
| 11 Month Change | -54.07% |
| 3 Month Change | -55.84% |
| 1 Year Change | -36.63% |
| 33 Year Change | -89.93% |
| 5 Year Change | -69.95% |
| Change since IPO | -54.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7D2A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -15.8% | -4.9% | -1.5% |
| 1Y | -36.6% | -5.6% | 7.9% |
Return vs Industry: 7D2A underperformed the German Medical Equipment industry which returned -4.2% over the past year.
Return vs Market: 7D2A underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| 7D2A volatility | |
|---|---|
| 7D2A Average Weekly Movement | 11.9% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7D2A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7D2A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 78 | Johannes Doll | www.sedanamedical.com |
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; and Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care, as well as AnaConDa, a medical device enabling administration of inhaled anaesthetics. It also provides FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; Scavenging tube, a one piece pre-connected tube designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; FlurAbsorb mount to hold the FlurAbsorb during scavenging of anesthetic gas; FlurAbsorb-S mount to hold the FlurAbsorb-S during scavenging of anesthetic gas; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and Mindray exhaust connector, which enables to connect the exhaust of the ventilator to an active or passive scavenging system.
Sedana Medical AB (publ) Fundamentals Summary
| 7D2A fundamental statistics | |
|---|---|
| Market cap | €91.88m |
| Earnings (TTM) | -€4.95m |
| Revenue (TTM) | €15.05m |
6.1x
P/S Ratio-18.6x
P/E RatioIs 7D2A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7D2A income statement (TTM) | |
|---|---|
| Revenue | SEK 174.14m |
| Cost of Revenue | SEK 51.20m |
| Gross Profit | SEK 122.95m |
| Other Expenses | SEK 180.19m |
| Earnings | -SEK 57.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 70.60% |
| Net Profit Margin | -32.87% |
| Debt/Equity Ratio | 0% |
How did 7D2A perform over the long term?
See historical performance and comparison